Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.62 |
| ▸ | NPY2R | P49146 | 8/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.62 |
| ▸ | NPY1R | P25929 | 6/20 | 0.62 |
| ▸ | TFPI | P10646 | 6/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.55 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.55 |
| ▸ | CALCR | P30988 | 2/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apidaecin SCHEMBL29380656 | 0.94 | NPY4R (0.67) | NPY4RNPY2RNPY5RNPY1RTFPI | |
| Apidaecin Ia SCHEMBL29458103 | 0.93 | NPY2R (0.63) | NPY4RNPY2RNPY5RNPY1RTFPI | |
| SCHEMBL29874441 | 0.87 | NPY2R (0.69) | NPY4RNPY2RNPY5RNPY1RTFPI | |
| Apidaecin Ia SCHEMBL31694517 | 0.85 | F2 (0.58) | NPY4RNPY2RNPY5RNPY1RRAMP3 | |
| SCHEMBL29702101 | 0.83 | F2 (0.58) | NPY4RNPY2RNPY5RNPY1RTFPI | |
| SCHEMBL29702111 | 0.83 | F2 (0.61) | NPY4RNPY2RNPY5RNPY1R | |
| SCHEMBL18872896 | 0.82 | AGTR1 (0.68) | NPY4RNPY2RNPY5RNPY1RAGTR1 | |
| Drosocin SCHEMBL29539177 | 0.81 | NPY2R (0.66) | NPY4RNPY2RNPY5RNPY1RTFPI | |
| SCHEMBL29358935 | 0.80 | TFPI (0.64) | NPY4RNPY2RNPY5RNPY1RTFPI | |
| SCHEMBL18872894 | 0.80 | AGTR1 (0.68) | NPY4RNPY2RNPY5RNPY1RAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | disclosed |
| US-20250368679-A1 | FORMATION OF AMIDINES | VANVELLER BRETT (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250281456-A1 | METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-09-11 | — | — | US | disclosed |
| CN-120574875-A | Method for constructing high-expression genetic engineering bacteria of antibacterial peptide APIDAECIN IB | 国家粮食和物资储备局科学研究院 | 2025-09-02 | — | — | CN | disclosed |
| CN-120574875-A | Method for constructing high-expression genetic engineering bacteria of antibacterial peptide APIDAECIN IB | 国家粮食和物资储备局科学研究院 | 2025-09-02 | — | — | CN | disclosed |
| US-12391733-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250256007-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CELLS | GELMEDIX INC (US) | 2025-08-14 | — | — | US | disclosed |
| WO-2025085609-A1 | ACRYLATED GELATIN POLYMER COMPOSITIONS COMPRISING CELLS | GELMEDIX, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4511075-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CELLS | Gelmedix, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023196891-A2 | METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023044389-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CORTICOSTEROIDS | GELMEDIX, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044385-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| US-20220288273-A1 | OSTEOINDUCTIVE MODIFIED GELATIN HYDROGELS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-15 | — | — | US | disclosed |
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022076505-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | RNMT, TRMT1L, UPF1 | NPY4R 2419/4885NPY2R 3305/4885NPY5R 3256/4885 |
| US-20250281456-A1 | METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS | DCK, DTYMK, POLK | NPY4R 4875/4885NPY2R 4862/4885NPY5R 4835/4885 |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | NPY4R 1871/4885NPY2R 2862/4885NPY5R 3059/4885 |
| US-20250368679-A1 | FORMATION OF AMIDINES | H1-4, H1-2, H1-3 | NPY4R 272/4885NPY2R 351/4885NPY5R 496/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | NPY4R 4239/4885NPY2R 4224/4885NPY5R 4145/4885 |
| US-12391733-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | VIP, SPPL2B, HM13 | NPY4R 3057/4885NPY2R 3252/4885NPY5R 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.